CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
DM Cordas dos Santos, T Tix, R Shouval… - Nature medicine, 2024 - nature.com
Although chimeric antigen receptor (CAR) T cell therapy represents a transformative
immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and …
immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …
2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
S Susanibar‐Adaniya, SK Barta - American journal of …, 2021 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
Next-generation CAR T-cell therapies
RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
CAR T-cell therapy for multiple myeloma: state of the art and prospects
Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …
Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma
Y Wang, J Cao, W Gu, M Shi, J Lan, Z Yan… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …